Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

Invitae data shows increased diagnosis rates with custom NGS technique allowing simultaneous genetic sequencing and copy number variant detection

October 17, 2017

Presentation at the American Society of Human Genetics Annual Meeting also highlights use of virtual panels to identify clinically important secondary findings

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, is presenting data showing genetic sequencing and copy number variant (CNV) detection performed together using expert-curated panels offers better diagnosis rates over sequencing alone in patients with neuromuscular disorders and childhood epilepsy. The studies are among the company’s 15 posters and presentations at the 2017 American ...

Read more


Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

Invitae Commences Exchange Offer for CombiMatrix Series F Warrants

October 06, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has commenced an offer to exchange (the “Exchange Offer”) each outstanding Series F warrant (CUSIP No. 20009T147) (the “CombiMatrix Series F Warrants”) to acquire one share of common stock of CombiMatrix Corporation (“CombiMatrix”) for 0.3056 of a share of common stock, par value $0.0001 per share, of Invitae (the “Invitae Common Stock”).

Upon the terms and subject to the conditions set forth ...

Read more


Invitae’s new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

Invitae’s new framework for classifying genetic variants aims to improve consistency of genetic test results industry-wide

October 05, 2017

Refinements to existing guidelines establish a more detailed and transparent approach for classifying variants at scale

As genetic testing grows both more complex and more integrated into mainstream medical care, continually improving how genetic variants are classified as pathogenic, benign or unknown is essential. Researchers with Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, have developed and validated a new framework that refines genetic variant classification guidelines, resulting in a more complete and consistent approach that ...

Read more


Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual Conference

Invitae Highlighting New Research, Expanded Suite of Services at National Society of Genetic Counselors (NSGC) 36th Annual Conference

September 13, 2017

Research highlights utility of proactive genetic screening in healthy adults

Award-winning genetic information tool added to support use of genetic information as part of mainstream medical care throughout life

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present initial findings showing proactive genetic health screening revealed medically significant findings for nearly one in five patients in a study presented at the National Society of Genetic Counselors (NSGC) 36th Annual Conference. The company will ...

Read more


Invitae to Present at the Cantor Fitzgerald Global Healthcare Conference

Invitae to Present at the Cantor Fitzgerald Global Healthcare Conference

September 13, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Katherine Stueland, chief commercial officer of Invitae, will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at approximately 11:30 a.m. Eastern / 8:30 a.m. Pacific in New York City.

The live, listen-only webcast may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available ...

Read more


Invitae to Participate in the Morgan Stanley 15th Annual Global Healthcare Conference

Invitae to Participate in the Morgan Stanley 15th Annual Global Healthcare Conference

August 29, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Monday, September 11, 2017 at approximately 3:40 p.m. Eastern / 12:40 p.m. Pacific in New York City.

The live, listen-only webcast may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay ...

Read more


Invitae Reports Second Quarter 2017 Results

Invitae Reports Second Quarter 2017 Results

August 07, 2017

Continued business momentum, double-digit sequential revenue growth and strengthened financial position

2017 volume guidance increased to 120,000-130,000 samples accessioned

Hosting conference call at 4:30 pm ET / 1:30 pm PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the quarter ended June 30, 2017.

Second Quarter 2017 Financial Highlights:

  • Generated revenue of $14.3 million in the second quarter of 2017, a 39% increase over the ...

Read more


Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

Invitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of Life

August 03, 2017

Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers

CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists

Invitae to Host Webcast for Investors on August 1 at 8 am ET / 5 am PT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held ...

Read more


Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results

Invitae Announces $73.5 Million Private Placement Offering to Fuel Strategic Growth Opportunities and Reports Preliminary Second Quarter Financial Results

August 03, 2017

Increasing momentum in Invitae’s business combined with offering proceeds position company to execute on near-term acquisition opportunities

Preliminary second quarter results demonstrate strong volume, revenue growth

Management raising guidance on 2017 volume to 120,000-130,000 samples

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, has entered into a definitive agreement to sell $73.5 million of Invitae stock in a private placement. The private placement is being led by existing investors with significant participation from ...

Read more


Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on  August 7, 2017

Invitae to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 7, 2017

July 24, 2017

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its second quarter 2017 financial results on Monday, August 7, 2017 and will host a conference call that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (844) 579-6824 for domestic callers and (763) 488-9145 for international callers, and the reservation number for ...

Read more